

FUNDED PROJECTS KWF PROGRAMME RESEARCH & IMPLEMENTATION CALL 2017-I

RESEARCH PROJECTS

| Project Number | Project Title | Project Leader | Institute | Department | Research Phase | Tumor type | Modality | Assigned Funder | Approved budget |
|----------------|---|----------------------------|---|---|----------------------|---|---------------------------|-----------------|-----------------|
| 10873 | Clinical evaluation of the benefit of planning based steering to improve effectiveness of hyperthermia in cervical cancer patients | Dr. Petra Kok | Academic Medical Center | Radiation Oncology (Radiotherapy) | Clinical | Cervical Cancer | Interventive devices | | € 326.486,80 |
| 10882 | Individualized image-guided adaptive radiotherapy for resectable gastric cancer: now and in the future | Dr. Astrid van der Horst | Academic Medical Center | Radiation Oncology (Radiotherapy) | Clinical | Stomach Cancer | Interventive devices | | € 611.236,60 |
| 10961 | Adjuvant hyperthermic intraperitoneal chemotherapy in patients with colon cancer at high risk of peritoneal carcinomatosis; the COLOPEC randomized multicentre trial. | Dr. Pieter Tanis | Academic Medical Center | Surgery | Clinical | Colon and Rectal Cancer | Interventive devices | | € 41.528,00 |
| 10992 | COMBATING THERAPY-INDUCED EPITHELIAL TO MESENCHYMAL TRANSITION IN ESOPHAGEAL CANCER | Dr. Maarten Bijlsma | Academic Medical Center | Center of Experimental and Molecular Medicine | Creation of modality | Oesophageal Cancer | Biomarkers | | € 583.890,26 |
| 11000 | Toxicity prediction in radiotherapy for pelvic cancers, assessing the added value of biological parameters to RT treatment planning variables | Prof. Coen Rasch | Academic Medical Center | Radiation Oncology (Radiotherapy) | Clinical | Bladder Cancer | Biomarkers | | € 680.516,00 |
| 11109 | Long-term outcomes of acute left-sided malignant colonic obstruction in the Netherlands; value of 'bridge-to-surgery' strategy. | Dr. Pieter Tanis | Academic Medical Center | Surgery | Clinical | Gastrointestinal Tract | Quality of life / care | | € 135.099,80 |
| 10948 | Targeting miR-139, a novel tumor suppressor in acute myeloid leukemia | Dr. Stefan Erkeland | Erasmus University Medical Center Rotterdam | Immunology | Basic research | Leukemia | Basic research | | € 598.347,00 |
| 10955 | The (cost)effectiveness of neoadjuvant FOLFIRINOX versus upfront surgery for (borderline) resectable pancreatic cancer. The PREOPANC-2 study. | Dr. Bas Groot Koerkamp | Erasmus University Medical Center Rotterdam | Surgery | Clinical | Pancreatic Cancer | Agents | Alpe d'HuZes | € 523.338,71 |
| 11008 | Dissecting the structural and molecular determinants of DNA replication stress in genome instability and tumorigenesis. | Dr. Arnab Ray Chaudhuri | Erasmus University Medical Center Rotterdam | Molecular Genetics | Basic research | Breast Cancer; Not Site-Specific Cancer | Basic research | | € 697.449,00 |
| 11086 | Realizing better doctor-patient dialogue about choices in palliative care and early-phase clinical trial participation: Towards an online value clarification tool. | Prof. Carin Van der Rijt | Erasmus University Medical Center Rotterdam | Medical Oncology | Clinical | Not Site-Specific Cancer | Quality of life / care | | € 586.466,50 |
| 11089 | Development of a radiolabeled necrosis-targeting probe for early detection of anti-cancer therapy efficacy and anti-cancer treatment: a new theranostic platform. | Prof. Clemens Löwik | Erasmus University Medical Center Rotterdam | Radiology / Nuclear Medicine | Creation of modality | Breast Cancer | Imaging | | € 451.048,00 |
| 11092 | Niche Inflammation and Clonal Evolution in Bone Marrow Failure and Leukemia | Dr. Marc Raaijmakers | Erasmus University Medical Center Rotterdam | Hematology | Credentialing | Leukemia | Basic research | | € 691.449,00 |
| 11143 | Boosting hyperthermia-based anticancer treatments by HSP90 inhibition | Prof. Roland Kanaar | Erasmus University Medical Center Rotterdam | Molecular Genetics | Credentialing | Bladder Cancer; Breast Cancer ; Head and Neck Cancer; Melanoma; Sarcoma (soft tissue); Urinary System | Agents | | € 591.391,00 |
| 10936 | Treating fear of cancer recurrence in primary care - effectiveness of a mental health worker led program | Dr. Marije van der Lee | Helen Dowling Instituut | Scientific Research | Clinical | Not Site-Specific Cancer | Quality of life / care | Alpe d'HuZes | € 398.308,85 |
| 11080 | Function and regulation of the fibrous corona of mitotic kinetochores in the protection of genome stability | Prof. Geert Kops | Hubrecht Institute | Hubrecht Institute (department) | Basic research | Not Site-Specific Cancer | Basic research | | € 636.620,50 |
| 11001 | Bacterial food poisoning and colon cancer; a cell biological and epidemiological study | Prof. Jacques Neeffjes | Leiden University Medical Center | Chemical Immunology | Credentialing | Colon and Rectal Cancer | Basic research | | € 571.699,00 |
| 10956 | The Orthopedia Homeobox transcription factor (OTP) in lung carcinoids: an indicator for metastatic progression or also a tumor suppressor? | Prof. Ernst Speel | Maastricht UMC+ (Maastricht University) | GROW, School for Oncology and Developmental Biology | Creation of modality | Lung Cancer | Biomarkers | | € 498.431,66 |
| 11044 | Energy balance, somatic mutations and metabolic subtypes in colorectal cancer: studying etiology and prognosis using molecular pathological epidemiology | Prof. Piet van den Brandt | Maastricht UMC+ (Maastricht University) | GROW, School for Oncology and Developmental Biology | Credentialing | Colon and Rectal Cancer | Lifestyle and exposure | | € 835.704,20 |
| 10894 | Achieving synergy between radiotherapy and immunotherapy to increase control of metastatic cancer | Dr. Inge Verbrugge | The Netherlands Cancer Institute | Tumor biology & Immunology | Basic research | Breast Cancer; Lung Cancer | Immune response modifiers | Alpe d'HuZes | € 679.585,00 |
| 10902 | New era of radiosensitization by modulating radiosensitizing agents during RT | Dr. Gerben Borst | The Netherlands Cancer Institute | Radiotherapy | Preclinical | Breast Cancer; Not Site-Specific Cancer | Interventive devices | | € 675.831,00 |
| 10933 | A risk prediction tool for cardiovascular disease in breast cancer patients | Prof. Flora E. van Leeuwen | The Netherlands Cancer Institute | Psychosocial Research and Epidemiology | Credentialing | Breast Cancer | Quality of life / care | Pink Ribbon | € 437.130,00 |
| 10999 | Mechanisms of DNA repair pathway control at DNA double-strand breaks and telomeres | Dr. Jacqueline Jacobs | The Netherlands Cancer Institute | Oncogenomics | Basic research | Not Site-Specific Cancer | Basic research | | € 596.318,00 |
| 11037 | Exploiting proline vulnerability for cancer therapy | Prof. Reuven Agami | The Netherlands Cancer Institute | Oncogenomics | Basic research | Not Site-Specific Cancer | Basic research | | € 807.549,00 |
| 11074 | Targeting replication rescue pathways | Prof. Hein te Riele | The Netherlands Cancer Institute | Tumor biology & Immunology | Basic research | Head and Neck Cancer | Basic research | | € 755.344,00 |
| 11079 | Cytotoxic T cell programming at the dendritic cell interface | Prof. Jannie Borst | The Netherlands Cancer Institute | Tumor biology & Immunology | Basic research | Not Site-Specific Cancer | Immune response modifiers | | € 618.318,00 |
| 11132 | Postpartum breast cancer diagnosed during involution: a distinct entity with unique clinicopathological, molecular and immunological features? | Prof. Frédéric Amant | The Netherlands Cancer Institute | Medical Oncology | Basic research | Breast Cancer | Basic research | | € 639.210,27 |
| 11165 | Radiosensitization of glioma through induction of mitotic enrichment | Dr. Olaf van Tellingen | The Netherlands Cancer Institute | Diagnostic Oncology | Preclinical | Brain Tumor | Agents | | € 394.321,50 |
| 11137 | The clonal relationship and mutational landscape of B-cell lymphoma recurrences: a key to tailored treatment | Prof. Han van Krieken | Radboud University Medical Center | Pathology | Credentialing | Hodgkin's Disease; Non-Hodgkin's Lymphoma | Biomarkers | | € 597.116,00 |

| | | | | | | | | | | |
|-------|--|----------------------------------|-------------------------------------|--|----------------------|--|---------------------------|--------------|---|------------|
| 10932 | MRI-guided focal salvage high dose rate brachytherapy for radio recurrent prostate cancer | Dr. Jochem van der Voort van Zyp | UMC Utrecht | Imaging | Clinical | Prostate Cancer | Interventive devices | | € | 323.925,60 |
| 10978 | Improved prediction and early detection of recurrent laryngeal carcinoma | Dr. Stefan Willems | UMC Utrecht | Laboratories & Pharmacy | Credentialing | Head and Neck Cancer | Biomarkers | | € | 497.402,00 |
| 11108 | Personalized strategy to avert drug resistance in hematologic cancers | Dr. Victor Peperzak | UMC Utrecht | Laboratories & Pharmacy | Creation of modality | Blood Cancer; Leukemia | Agents | Alpe d'HuZes | € | 516.464,00 |
| 11110 | Cognitive Functioning After Brain Irradiation Informed by MRI | Dr. ir. Marielle Philippens | UMC Utrecht | UMC Utrecht Cancer Center | Credentialing | Not Site-Specific Cancer | Imaging | | € | 635.728,50 |
| 11111 | EORTC-1308: Radiation versus Observation following surgical resection of Atypical Meningioma: a randomised controlled trial (The ROAM trial) | Dr. Joost Verhoeff | UMC Utrecht | UMC Utrecht Cancer Center | Clinical | Nervous System | Interventive devices | | € | 56.476,00 |
| 10861 | Accelerated ageing in cancer survivors: Senescence EARly after Chemotherapy for testicular cAnceR treatment: Time to act (SEACAT) | Prof. Jourik Gietema | University Medical Center Groningen | Medical Oncology | Clinical | Testicular Cancer | Quality of life / care | | € | 746.132,00 |
| 10989 | Characterization of UV-induced senescent cells during melanoma progression | Dr. Marco Demaria | University Medical Center Groningen | Ageing Biology | Basic research | Melanoma | Basic research | | € | 615.475,00 |
| 11010 | Modulation of the TSC-mTORC1-mitochondrial pathway for suppression of MYC-driven tumourigenesis | Prof. Cor Calkhoven | University Medical Center Groningen | Ageing Biology | Basic research | Blood Cancer; Leukemia; Lung Cancer | Basic research | | € | 647.459,00 |
| 11013 | Using the plasma membrane proteome to dissect clonal heterogeneity and track disease progression in AML | Prof. Jan Jacob Schuringa | University Medical Center Groningen | Hematology | Basic research | Leukemia | Basic research | | € | 579.402,00 |
| 11062 | Towards evidence-based and broadly supported protocols for cancer follow-up in primary care | Dr. Annette Berendsen | University Medical Center Groningen | General Practice | Creation of modality | Breast Cancer; Colon and Rectal Cancer | Quality of life / care | | € | 276.605,57 |
| 11072 | EORTC-1301-LG: 10-day decitabine versus conventional chemotherapy ("3+7") followed by allografting in AML patients ≥ 60 years (extension approved KWF grant) | Prof. Gerwin Huls | University Medical Center Groningen | Hematology | Clinical | Leukemia | Agents | | € | 139.150,00 |
| 11082 | Dissecting the role of aberrant Wnt signaling in breast cancer | Dr. Renee van Amerongen | University of Amsterdam | Swammerdam Institute for Life Sciences | Basic research | Breast Cancer | Basic research | | € | 517.035,00 |
| 10967 | Unraveling the role of signaling networks controlled by Grainyhead like transcription factor in breast cancer subtypes | Dr. Erik Danen | University of Leiden | Leiden Academic Centre for Drug Research (LACDR) | Basic research | Breast Cancer | Basic research | | € | 495.692,80 |
| 11038 | Drug-atlas based prediction of multi-drug combinations against glioblastoma | Dr. Bart Westerman | VU University Medical Centre | Neurosurgery (VUmc CCA) | Basic research | Nervous System | Agents | | € | 444.503,90 |
| 11065 | Exosomes-driven alterations of mesenchymal stem cell immunomodulatory properties as novel therapeutic targets for osteosarcoma | Dr. Serena Rubina Baglio | VU University Medical Centre | Pathology (VUmc CCA) | Credentialing | Bone Cancer | Immune response modifiers | | € | 523.532,95 |

Total funding Research Projects (43 projects): € 22.674.717,97

YOUNG INVESTIGATOR GRANTS

| Project Number | Project Title | Project Leader | Institute | Department | Research Phase | Tumor type | Mission Goal(s) | Assigned Funder | Approved budget |
|----------------|---|----------------------------------|---|--|----------------------|---|---------------------------|-----------------|-----------------|
| 11053 | ER-stress and Grp78 during intestinal carcinogenesis | Dr. Jarom Heijmans | Academic Medical Center | Tytgat Institute for Liver and Intestinal Research | Basic research | Colon and Rectal Cancer | Basic research | Alpe d'HuZes | € 613.505,75 |
| 11031 | Dissecting the mechanisms of malignant transformation in del(5q) myelodysplastic syndrome to selectively target the disease-initiating hematopoietic stem cells | Dr. Rebekka Schneider-Kramann | Erasmus University Medical Center Rotterdam | Hematology | Basic research | Blood Cancer | Basic research | Alpe d'HuZes | € 506.273,00 |
| 10895 | The causes and effect of variation in the curative treatment of esophageal and gastric cancer: A mixed methods approach | Dr. Rob Verhoeven | IKNL | Research | Credentialing | Oesophageal; Stomach Cancer | Quality of life / care | Alpe d'HuZes | € 551.465,90 |
| 11056 | Oncolytic viruses, a generic approach to sensitize tumours for cancer immunotherapy | Dr. Nadine Pronk - van Montfoort | Leiden University Medical Center | Clinical Oncology | Credentialing | Head and Neck Cancer, Melanoma; Ovarian Cancer; Pancreatic Cancer; Vaginal Cancer; Vulva Cancer | Immune response modifiers | Alpe d'HuZes | € 518.687,72 |
| 10911 | ROGUE: Radiosensitization Of high-grade Glioma and diffuse intrinsic pontine glioma by focused Ultrasound-mediated drug Engagement | Dr. Dannis Van Vuurden | Princess Maxima Center for Pediatric Oncology | Research Operations | Creation of modality | Nervous System | Agents | Alpe d'HuZes | € 499.965,00 |
| 10957 | The RSPO-LGR signaling pathway as a driver of breast cancer | Dr. Elvira Bakker | UMC Utrecht | Laboratories & Pharmacy | Basic research | Breast Cancer | Basic research | Alpe d'HuZes | € 665.465,55 |
| 10851 | Precision Thyroid cAnceR surgery with intraoperative molecular fluoRescent Guided imaging to rEduce overtreatment and postoperative morbidity (TARGET) | Dr. Schelto Kruijff | University Medical Center Groningen | Surgery | Clinical | Thyroid Cancer | Interventive devices | Alpe d'HuZes | € 611.684,00 |
| 10913 | TArgeting Metabolism to Improve response to immune-Checkpoint inhibition in melanoma (TAMIC) | Dr. Mathilde Jalving | University Medical Center Groningen | Medical Oncology | Clinical | Melanoma | Agents | Alpe d'HuZes | € 477.492,40 |
| 11148 | Preventing radiation-induced neurocognitive dysfunction in patients with paediatric brain tumours: biological mechanisms and potential role of proton therapy | Dr. Lara Barazzuol | University Medical Center Groningen | Radiotherapy | Creation of modality | Brain Tumor | Quality of life / care | Alpe d'HuZes | € 495.958,50 |
| 10960 | Towards OPTimal Timing and Method for promoting sUSTained adherence to lifestyle and body weight recommendations in postMenopausal breast cancer survivors. | Dr. Meeke Hoedjes | VU University Amsterdam | Health Sciences (FALW) | Basic research | Breast Cancer | Lifestyle and exposure | Alpe d'HuZes | € 505.432,80 |

Total funding Young Investigator Grants (10 projects): € 5.445.930,62

CONSORTIA

| Project Number | Project Title | Project Leader | Institute | Department | Research Phase | Tumor type | Mission Goal(s) | Assigned Funder | Approved budget |
|----------------|---|------------------------|----------------------------------|--|----------------------|-----------------------------------|---------------------------|-----------------|-----------------|
| 11157 | NeoVAC: a novel nanotechnology platform using neoantigen-encoding DNA for personalised specific immunotherapy | Prof. Ferry Ossendorp | Leiden University Medical Center | Immunohematology and Blood Transfusion | Creation of modality | Colon and Rectal Cancer; Melanoma | Immune response modifiers | | € 705.363,00 |
| 11105 | Improving breast cancer screening among young high risk women by blood-based methods | Dr. Esther Lips | The Netherlands Cancer Institute | Molecular Pathology | Credentialing | Breast Cancer | Biomarkers | Pink Ribbon | € 605.849,50 |
| 11026 | Glioma Longitudinal Analysis in the Netherlands (GLASS-NL): Molecular and imaging markers for malignant evolution of IDH-mutant astrocytomas. | Prof. Pieter Wesseling | VU University Medical Centre | Pathology (VUmc CCA) | Credentialing | Brain Tumor | Biomarkers | | € 1.218.641,20 |

Total funding Consortia (3 projects): € 2.529.853,70

UNIQUE HIGH RISK PROJECTS

| Project Number | Project Title | Project Leader | Institute | Department | Research Phase | Tumor type | Mission Goal(s) | Assigned Funder | Approved budget |
|----------------|---|------------------------|--|---|----------------------|---|---------------------------|-----------------|-----------------|
| 10906 | TRACE and RECALL clonal population dynamics to model colorectal cancer tumor growth | Dr. Nicolas Leveille | Academic Medical Center | Center of Experimental and Molecular Medicine | Basic research | Colon and Rectal Cancer | Basic research | Alpe d'HuZes | € 149.695,00 |
| 11011 | Developing a validated Cancer-on-Chip prototype for personalized medicine | Dr. Dik van Gent | Erasmus University Medical Center Rotterdam | Molecular Genetics | Credentialing | Breast Cancer | Biomarkers | Alpe d'HuZes | € 170.420,00 |
| 11125 | Nuclear EGFR in Glioblastomas as a target for therapy | Dr. Pim French | Erasmus University Medical Center Rotterdam | Neurology | Basic research | Brain Tumor | Basic research | Alpe d'HuZes | € 165.042,00 |
| 11163 | Trojan horses against cancer: the use of harmless clostridia bacteria to continuously produce immunomodulatory anti-cancer agents specifically within the tumor | Prof. Philippe Lambin | Maastricht UMC+ (Academic Hospital Maastricht) | Academic Hospital Maastricht (azM) | Creation of modality | Not Site-Specific Cancer | Immune response modifiers | Alpe d'HuZes | € 152.042,00 |
| 11117 | Challenging the dogmatic use of ABL1-directed tyrosine kinase inhibitors in BCR-ABL1-positive acute lymphoblastic leukemia | Prof. Monique den Boer | Princess Maxima Center for Pediatric Oncology | Research Operations | Credentialing | Leukemia | Biomarkers | Alpe d'HuZes | € 149.028,00 |
| 10944 | Tailored lymphadenectomy using Sentinel node Navigation surgery in submucosal esophageal Adenocarcinoma Patients: SNAP-II study | Prof. Bas Weusten | UMC Utrecht | Internal Medicine & Dermatology | Clinical | Oesophageal | Interventive devices | Alpe d'HuZes | € 201.484,50 |
| 11077 | Towards understanding molecular and pre-clinical aspects of loss of protein homeostasis in cancer. | Dr. Tobias Dansen | UMC Utrecht | Biomedical Genetics | Basic research | Colon and Rectal Cancer; Not Site-Specific Cancer | Basic research | Alpe d'HuZes | € 267.388,50 |
| 11040 | Exploring the immunomodulatory activity of galectin-cytokine interactions | Dr. Victor Thijssen | VU University Medical Centre | Radiation Oncology (VUmc CCA) | Basic research | Not Site-Specific Cancer | Basic research | Alpe d'HuZes | € 173.819,50 |

Total funding Unique High Risk Projects (8 projects): € 1.428.919,50

INFRASTRUCTURAL INITIATIVES

| Project Number | Project Title | Project Leader | Institute | Approved budget |
|----------------|---|----------------------------|-------------------------------------|-----------------|
| 8223 | Facilitating power: collecting and managing international data on (rare) colorectal cancer predisposition syndromes. | Dr. M. Nielsen | Leiden University Medical Center | € 45.560,48 |
| 8242 | Dutch Hepatocellular Carcinoma Group biobank and prospective database | Dr. M.J. Coenraad | Leiden University Medical Center | € 440.251,00 |
| 8231 | CustoMICE: a facility for production and distribution of engineered mouse models for cancer research | Prof. ir. J. Jonkers | The Netherlands Cancer Institute | € 866.548,00 |
| 8237 | Biobank of 5-year lymphoma survivors as a resource to examine susceptibility genes and biomarkers for late effects of cancer treatment. | Prof. ir. F.E. van Leeuwen | The Netherlands Cancer Institute | € 938.388,60 |
| 8244 | Netherlands facility for Cancer-Immune Analysis (N-CIA) | Prof. T.N.M. Schumacher | The Netherlands Cancer Institute | € 3.648.008,40 |
| 8254 | Proton therapy research infrastructure - ProTRAIT | Prof. J.A. Langendijk | University Medical Center Groningen | € 1.545.098,60 |
| 8225 | GENomics portal for precision medicine research in ONCOlogy: GENONCO | Prof. ir. E. Cuppen | UMC Utrecht | € 1.600.778,00 |

Total funding Infrastructural initiatives (7 projects): € 9.084.633,08

IMPLEMENTATION PROJECTS

| Project Number | Project Title | Project Leader | Institute | Approved budget |
|----------------|--|------------------------|-----------------------------------|-----------------|
| 8281 | Nationwide implementation of standardized structured reporting to support optimal treatment decisions | Dr. R.P.M.G. Hermens | Radboud University Medical Center | € 264.352,43 |
| 8272 | Postoperative Standardization of Care; the implementation of best practice after pancreatic resection (PORSCH trial) | Dr. H.C. van Santvoort | UMC Utrecht | € 555.422,00 |

Total Funding Implementation projects (2 projects): € 819.774,43

Total funding CALL 2017-I: € 41.983.829,30

OVERVIEW

| Research tracks & research phases | Number of projects | Funding |
|------------------------------------|--------------------|------------------------|
| Exploration track | 38 | € 20.970.175,54 |
| Basic research | 23 | € 12.374.930,57 |
| Credentialing | 15 | € 8.595.244,97 |
| Development track | 26 | € 11.109.246,25 |
| Creation of modality | 9 | € 4.179.767,99 |
| Preclinical | 2 | € 1.070.152,50 |
| Clinical | 15 | € 5.859.325,76 |
| Infrastructural initiatives | 7 | € 9.084.633,08 |
| Implementation projects | 2 | € 819.774,43 |
| Total | 73 | € 41.983.829,30 |

| Funding types & research phases | Number of projects | Funding |
|----------------------------------|--------------------|------------------------|
| Consortia | 3 | € 2.529.853,70 |
| Creation of modality | 1 | € 705.363,00 |
| Credentialing | 2 | € 1.824.490,70 |
| Research Project | 43 | € 22.674.717,97 |
| Basic research | 15 | € 9.328.308,47 |
| Credentialing | 9 | € 5.381.152,65 |
| Creation of modality | 5 | € 2.326.439,49 |
| Preclinical | 2 | € 1.070.152,50 |
| Clinical | 12 | € 4.568.664,86 |
| Unique High Risk Project | 8 | € 1.428.919,50 |
| Basic research | 4 | € 755.945,00 |
| Credentialing | 2 | € 319.448,00 |
| Creation of modality | 1 | € 152.042,00 |
| Clinical | 1 | € 201.484,50 |
| Young Investigator Grant | 10 | € 5.445.930,62 |
| Basic research | 4 | € 2.290.677,10 |
| Creation of modality | 2 | € 995.923,50 |
| Clinical | 2 | € 1.089.176,40 |
| Credentialing | 2 | € 1.070.153,62 |
| Infrastructure | 7 | € 9.084.633,08 |
| Implementation | 2 | € 819.774,43 |
| Total funding CALL 2017-1 | 73 | € 41.983.829,30 |